Stoke Therapeutics (STOK) Leases (2020 - 2026)

Stoke Therapeutics has reported Leases for 7 years, with the latest figure at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 34.93% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (down 34.93% YoY), and the FY2025 full-year result was $3.1 million, down 28.63% from the prior year.
• Leases for Q1 2026 stood at $2.5 million, down from $3.1 million in the prior quarter.
• The five-year high for Leases was $6.1 million in Q1 2024, with the low at $2.5 million in Q1 2026.
• Average Leases over 5 years is $4.3 million, with a median of $4.2 million recorded in 2023.
• Year-over-year, Leases soared 733.0% in 2022 and tumbled 41.76% in 2023.
• Tracing STOK's Leases over 5 years: stood at $4.8 million in 2022, then retreated by 13.74% to $4.1 million in 2023, then rose by 5.98% to $4.3 million in 2024, then retreated by 28.63% to $3.1 million in 2025, then slipped by 19.61% to $2.5 million in 2026.
• The last three Leases figures came in at $2.5 million (Q1 2026), $3.1 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.

Peer Comparison